- Home
- PLYX vs COYA Comparison
PLYX vs COYA Comparison
Compare PLYX & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLYX | COYA |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.7M | 110.0M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PLYX | COYA |
|---|---|---|
| Price | $2.05 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $15.80 |
| AVG Volume (30 Days) | 97.6K | ★ 103.0K |
| Earning Date | 05-22-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.53 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $1.85 | $3.71 |
| 52 Week High | $9.18 | $7.75 |
Technical Indicators
Market Signals| Indicator | PLYX | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 43.22 |
| Support Level | $1.97 | $4.45 |
| Resistance Level | $2.39 | $5.19 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 21.08 | 6.41 |
Price Performance
Historical ComparisonAbout PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.